Dual NLCs had the greatest therapeutic efficacy because to their improved in vitro cytotoxicity and apoptosis, longer survival rate, and excellent anti-glioma behavior in mice with intracranial gliomas. Overall, the targeting platform created for this work can deliver BTZ to glioma cells and overcome several difficulties to treat advanced brain cancer with potential therapeutic results. This evidence concerns the gene CASC3 and central nervous system cancer.